SCHEMBL2454840

SCHEMBL2454840

C=CCc1c(O)ccc(Cl)c1CC=C

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SRD5A1 P18405 1/20 0.45
XDH P47989 2/20 0.44
GABRA1 P14867 5/20 0.42
GABRB2 P47870 5/20 0.42
ALDH1A1 P00352 3/20 0.42
MEN1 O00255 2/20 0.42
GAA P10253 2/20 0.42
MAPT P10636 2/20 0.42
CNR1 P21554 2/20 0.42
CNR2 P34972 2/20 0.42
KMT2A Q03164 2/20 0.42
AKR1B1 P15121 2/20 0.42
KDM4E B2RXH2 1/20 0.42
ALDH2 P05091 1/20 0.42
HPGD P15428 1/20 0.42
PPARG P37231 1/20 0.42
PPARD Q03181 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
CYP3A4 P08684 3/20 0.38
MAPK1 P28482 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8521835 0.88 CYP3A4 (0.48) SRD5A1XDHGABRA1GABRB2ALDH1A1
SCHEMBL323547 0.87 XDH (0.54) SRD5A1XDHGABRA1GABRB2ALDH1A1
SCHEMBL10639712 0.86 CYP3A4 (0.46) SRD5A1XDHGABRA1GABRB2ALDH1A1
Hydrogen Sulfide SCHEMBL6721312 0.84 XDH (0.52) SRD5A1XDHGABRA1GABRB2ALDH1A1
SCHEMBL10400349 0.82 SRD5A1 (0.41) SRD5A1XDHGABRA1GABRB2ALDH1A1
SCHEMBL5274928 0.82 TSHR (0.45) SRD5A1XDHGABRA1GABRB2ALDH1A1
SCHEMBL16685089 0.81 GABRA1 (0.39) SRD5A1XDHGABRA1GABRB2ALDH1A1
SCHEMBL6013229 0.80 GABRA1 (0.52) SRD5A1XDHGABRA1GABRB2ALDH1A1
SCHEMBL45432 0.77 GABRA1 (0.53) SRD5A1XDHGABRA1GABRB2ALDH1A1
SCHEMBL6398012 0.76 SRD5A1 (0.49) SRD5A1XDHGABRA1GABRB2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7179849-B2 Antimicrobial compositions containing colloids of oligodynamic metals C. R. BARD, INC. (US) 2007-02-20 US claimed
EP-2948256-B1 ANTISEPTIC APPLICATOR CAREFUSION 2200 INC (US) 2022-12-14 EP disclosed
EP-2173428-B1 FOLEY CATHETER HAVING STERILE BARRIER BARD INC C R (US) 2018-10-10 EP disclosed
EP-2948256-A1 ANTISEPTIC APPLICATOR CareFusion 2200 Inc. (US) 2015-12-02 EP disclosed
US-9119946-B2 Antiseptic applicator CAREFUSION 2200, INC. (US) 2015-09-01 US disclosed
US-9084838-B2 Feminine care absorbent article for use in warm climates KIMBERLY-CLARK WORLDWIDE, INC. (US) 2015-07-21 US disclosed
WO-2014116482-A1 ANTISEPTIC APPLICATOR CAREFUSION 2200, INC. (US) 2014-07-31 WO disclosed
US-20140205360-A1 ANTISEPTIC APPLICATOR CAREFUSION 2200, INC. (US) 2014-07-24 US disclosed
US-8383164-B2 Antiviral composition and method for using the same INNOVASOURCE LLC (US) 2013-02-26 US disclosed
WO-2012104738-A2 FEMININE CARE ABSORBENT ARTICLE FOR USE IN WARM CLIMATES KIMBERLY-CLARK WORLDWIDE, INC. (US) 2012-08-09 WO disclosed
US-20070048345-A1 Antimicrobial composition KIMBERLY-CLARK WORLDWIDE, INC. 2007-03-01 US disclosed
US-7179849-B2 Antimicrobial compositions containing colloids of oligodynamic metals C. R. BARD, INC. (US) 2007-02-20 US disclosed
US-20050042266-A1 Cyanoacrylate compositions containing anti-microbial agent CLOSURE MEDICAL CORPORATION (US) 2005-02-24 US disclosed
EP-1508601-A1 Cyanoacrylate compositions containing anti-microbial agent Closure Medical Corporation (US) 2005-02-23 EP disclosed
EP-1448503-A1 PROCESS FOR PREPARING 3,3',6,6'-TETRAALKYL-2,2'-BIPHENOLS AND 3,3',6,6'-TETRAALKYL-5,5'-DIHALO-2,2'-BIPHENOLS INVISTA Technologies S.à.r.l. (US) 2004-08-25 EP disclosed
US-20040116551-A1 Antimicrobial compositions containing colloids of oligodynamic metals C.R. BARD, INC. 2004-06-17 US disclosed
WO-2004017738-A1 ANTIMICROBIAL COMPOSITIONS CONTAINING COLLOIDS OF OLIGODYNAMIC METALS C.R. BARD, INC. (US) 2004-03-04 WO disclosed
WO-2003045884-A1 PROCESS FOR PREPARING 3,3',6,6'-TETRAALKYL-2,2'-BIPHENOLS AND 3,3',6,6'-TETRAALKYL-5,5'-DIHALO-2,2'-BIPHENOLS E.I. DU PONT DE NEMOURS AND COMPANY (US) 2003-06-05 WO disclosed
US-6503952-B2 Mixture of chlorhexidine, quaternary ammonium salt and chlorinated phenol THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK 2003-01-07 US disclosed
US-20010016589-A1 Mixture of chlorhexidine, quaternary ammonium salt and chlorinated phenol TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK, THE 2001-08-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070048345-A1 Antimicrobial composition MGAM, CUTA, CD68 SRD5A1 4674/4885XDH 1565/4885GABRA1 3280/4885
US-20050042266-A1 Cyanoacrylate compositions containing anti-microbial agent CLSPN, PCNA, CDC73 SRD5A1 4233/4885XDH 1979/4885GABRA1 2131/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.